Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NAUT
stocks logo

NAUT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.140
-0%
--
--
-0.165
+26.92%
--
--
-0.150
+25%
Estimates Revision
The market is revising No Change the revenue expectations for Nautilus Biotechnology, Inc. (NAUT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 213.16%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.89%
In Past 3 Month
Stock Price
Go Up
up Image
+213.16%
In Past 3 Month
Wall Street analysts forecast NAUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAUT is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast NAUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAUT is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.070
sliders
Low
2.50
Averages
2.50
High
2.50
Current: 2.070
sliders
Low
2.50
Averages
2.50
High
2.50
Goldman Sachs
Matthew Sykes
Hold
to
Strong Sell
Downgrades
$2.25 → $1.75
2024-12-05
Reason
Goldman Sachs
Matthew Sykes
Price Target
$2.25 → $1.75
2024-12-05
Downgrades
Hold
to
Strong Sell
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nautilus Biotechnology Inc (NAUT.O) is -3.42, compared to its 5-year average forward P/E of -6.59. For a more detailed relative valuation and DCF analysis to assess Nautilus Biotechnology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.59
Current PE
-3.42
Overvalued PE
0.39
Undervalued PE
-13.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.30
Undervalued EV/EBITDA
-6.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
525.88
Current PS
0.00
Overvalued PS
1663.94
Undervalued PS
-612.18
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 499900% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NAUT News & Events

Events Timeline

(ET)
2025-11-03
08:13:39
Nautilus reveals the setup and testing of its external field evaluation unit.
select
2025-10-28 (ET)
2025-10-28
08:04:57
Nautilus Biotechnology announces Q3 EPS of 11 cents, compared to a loss of 13 cents last year.
select
2025-07-31 (ET)
2025-07-31
08:03:58
Nautilus Biotechnology reports Q2 EPS (12c) vs (14c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
10-29NASDAQ.COM
Nautilus (NAUT) Third Quarter 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
9.0
10-23NASDAQ.COM
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

  • Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.

  • Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.

  • Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.

  • Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.

[object Object]
Preview
5.0
09-11NASDAQ.COM
Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth

  • Biotech Stocks Momentum: Several small-cap biotech stocks, including Nautilus Biotechnology and PepGen, are experiencing renewed investor interest due to insider buying, strategic partnerships, and clinical trial advancements, leading to notable after-hours gains.

  • Nautilus Biotechnology Highlights: Nautilus saw a significant rise in stock price following insider purchases by its CEO and a partnership with the Allen Institute, alongside a reported narrower loss and strong cash position.

  • Lixte Biotechnology's Financial Strategy: Lixte announced a $2.6 million investment in Bitcoin and Ethereum to diversify its treasury, reflecting a strategic shift aimed at enhancing flexibility in the digital economy.

  • RenovoRx and VolitionRx Developments: RenovoRx received positive feedback for its pancreatic cancer trial and is expanding commercialization efforts, while VolitionRx entered a partnership to advance its diagnostic technology for Antiphospholipid Syndrome.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nautilus Biotechnology Inc (NAUT) stock price today?

The current price of NAUT is 2.07 USD — it has decreased -0.48 % in the last trading day.

arrow icon

What is Nautilus Biotechnology Inc (NAUT)'s business?

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

arrow icon

What is the price predicton of NAUT Stock?

Wall Street analysts forecast NAUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAUT is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nautilus Biotechnology Inc (NAUT)'s revenue for the last quarter?

Nautilus Biotechnology Inc revenue for the last quarter amounts to -15.47M USD, decreased -18.99 % YoY.

arrow icon

What is Nautilus Biotechnology Inc (NAUT)'s earnings per share (EPS) for the last quarter?

Nautilus Biotechnology Inc. EPS for the last quarter amounts to -11452000.00 USD, decreased -17.15 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nautilus Biotechnology Inc (NAUT)'s fundamentals?

The market is revising No Change the revenue expectations for Nautilus Biotechnology, Inc. (NAUT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 213.16%.
arrow icon

How many employees does Nautilus Biotechnology Inc (NAUT). have?

Nautilus Biotechnology Inc (NAUT) has 155 emplpoyees as of December 05 2025.

arrow icon

What is Nautilus Biotechnology Inc (NAUT) market cap?

Today NAUT has the market capitalization of 261.45M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free